Skip to main content
Fig. 4 | Cancer Cell International

Fig. 4

From: Recognize the role of CD146/MCAM in the osteosarcoma progression: an in vitro study

Fig. 4

Effects of OS CM on progression of HUVECs in vitro. The proliferation (A) and permeability (B) of HUVECs were analyzed by MTT and Endothelial permeability assays, after HUVECs were treated with OS CM for 72 h or 24 h, respectively. (C) The migration capability of HUVECs was measured using a Transwell system after HUVECs were cultured in MG63 CM for 24 h. Scale: × 100. D, E Tube formation and diameter size were analyzed after HUVECs were incubated in MG63 CM for 24 h. The quantification of the tube length and diameter was done by Image J software and is presented in the histogram right. Bar = 400 μm. *P < 0.05; **P < 0.01; ***P < 0.001. The data were average results of experiments repeated for six (A), three (B, D), four (C), and at least eight (E) times, respectively

Back to article page